India’s New CAR-T Product Is A First For Emerging Markets, But Barriers Remain For India In Becoming A Cancer Innovation Hub
Pharmaceuticals / India / Wed 01 May, 2024
Key View
- Access to cell therapies will improve across emerging markets following the approval and market launch of the first India-produced CAR-T cell therapy.
- Aging populations and low health expenditure will continue to drive demand for lower-cost cancer therapies.
- Growing demand for cancer care in India will put pressure on the government to grow